ArticleJournal of ovarian research2025
Diosmetin ameliorates inflammation and apoptosis in the pathomechanism of PCOS through the NRF2/AKT/PPARγ signalling pathway.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Network-based prioritization of sepsis-associated metabolites and in vivo validation of diosmetin in sepsis-associated acute kidney injury.Molecular biology reports · 2026Article
- Diosmetin alleviates retinal ischemia-reperfusion injury through SIRT1-mediated suppression of oxidative stress, inflammation, and PANoptosis.Immunologic research · 2026Article
- Lemongrass (Biochemistry research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
ethnopharmacological relevanceDiosmetin (DIO) is a flavonoid extracted from the traditional Chinese medicine Schizonepeta tenuifolia Briq. The anti-inflammatory and neuroprotective properties of DIO have shown promise. However, the underlying mechanisms need further elucidation. STUDY
aimThis research aimed to explore how DIO reduces oxidative stress and inflammation in the ovaries and slows the pathological development of polycystic ovary syndrome by influencing the AKT/PPARγ signalling pathway. MATERIALS AND
methodsDIO targets were screened via network pharmacology tools. The protective effect of DIO on polycystic ovary syndrome was assessed via haematoxylin‒eosin (H&E) staining. Immunohistochemical staining, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence were used to determine the effects of DIO on ovarian granulosa cell inflammation. In addition, we performed Western blotting to determine the expression of TNF-α, IL-6 and AKT/PPARγ pathway proteins.
resultsThis research demonstrated an increase in TNF-α and IL-6 expression in a rat model of polycystic ovary syndrome (PCOS) induced by letrozole. Histological analysis indicated that the ovaries of rats in the PCOS group showed significant follicular loss and vacuolation changes compared with those in the normal control (NC) group. Treatment with DIO improved the cystic changes in the ovaries. Metabolic assessments revealed that the PCOS group presented significantly altered levels of FSH (4.2 ± 0.3 IU/L), TG (0.65 ± 0.2 mmol/L), E2 (106 ± 14 pg/L), TC (3.9 ± 0.7 mmol/L), LH (7.8 ± 0.2 IU/L), and TEST (11 ± 3 ng/mL) compared with those in the NC group (FSH: 6.3 ± 1.7 IU/L; TG: 1.2 ± 0.2 mmol/L; E2: 147 ± 21 pg/mL; TC: 2.2 ± 0.4 mmol/L; LH: 5.8 ± 1.2 IU/L; and TEST: 5.5 ± 2 ng/mL), indicating hyperandrogenaemia. Additionally, at the conclusion of the study, the PCOS group (310 ± 7 g) presented a significant increase in body weight compared with the NC group (310 ± 7 g), whereas treatment with 50 mg/kg DIO (351 ± 6 g) or 100 mg/kg DIO (342 ± 8 g) mitigated this weight gain. Immunohistochemistry, Western blot, and immunofluorescence results revealed that DIO reduced inflammation and alleviated the pathological changes associated with PCOS. Furthermore, DIO improved the inflammatory condition of the ovaries in the PCOS group by inhibiting the AKT/PPARγ signalling pathway. The suppression of AKT and PPARγ diminished the anti-inflammatory effects of DIO. Additionally, DIO countered inflammation and apoptosis in testosterone-induced ovarian granulosa cells by enhancing the expression of AKT/PPARγ signalling.
conclusionThe present study confirms that DIO has important therapeutic potential for treating polycystic ovary syndrome by inhibiting ovarian inflammation and oxidative stress through the modulation of AKT/PPARγ signalling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.